In the quest to unravel the intricate brain injuries underlying neonatal encephalopathy, magnetic resonance imaging (MRI) has emerged as the definitive tool. Unlike other imaging modalities, MRI offers unparalleled soft tissue contrast and exquisite anatomical detail, essential for delineating the extent and pattern of cerebral injury. Among MRI techniques, diffusion-weighted imaging (DWI) has revolutionized early detection capabilities, as it sensitively captures the early cytotoxic edema that typifies hypoxic-ischemic injury. Through the measurement of water molecule displacement at a microscopic scale, DWI allows clinicians to detect brain areas undergoing acute stress within hours of insult, dramatically influencing therapeutic decisions.

Complementing DWI, proton magnetic resonance spectroscopy (^1H-MRS) provides a metabolic window into the infant brain. This technique measures the concentration of various brain metabolites, with the lactate to N-acetylaspartate (Lac/NAA) peak area ratio serving as a particularly reliable biomarker. Elevated lactate reflects anaerobic metabolism induced by hypoxia, while reductions in NAA signify neuronal loss or dysfunction. The combined assessment from the basal ganglia and thalamus regions affords a robust biochemical signature that correlates strongly with two-year neurodevelopmental outcomes. Such molecular insights extend beyond anatomical imaging, offering predictive power that guides clinical management and family counseling.

The development of multimodal MRI scoring systems marks a significant leap forward in the prognostic evaluation of NE. By integrating data from conventional MRI, DWI, and MRS, these composite scales achieve superior correlation with neurodevelopmental milestones, facilitating individualized prognosis. The synergy achieved in combining structural and metabolic information underscores the necessity of comprehensive imaging approaches. Each modality captures different facets of the brain’s injury landscape – from gross anatomical disruptions to subtle biochemical alterations – rendering a holistic perspective that no solitary method can provide.

Beyond the traditional realms of MRI and spectroscopy, advances in neuroimaging continue to push the boundaries of understanding neonatal brain injury at a microstructural and functional level. Diffusion tensor imaging (DTI) dissects white matter integrity by tracking anisotropic water diffusion along axonal tracts, shedding light on connectivity disruptions invisible on standard MRI. Similarly, arterial spin labeling (ASL) non-invasively measures cerebral perfusion by magnetically tagging blood water molecules, allowing assessment of regional blood flow changes in compromised brain regions. Functional MRI, harnessing blood oxygen level-dependent (BOLD) contrast, offers dynamic insights into brain activity and network connectivity, potentially unmasking functional deficits that arise from injury.

Standardization emerges as a crucial theme in advancing MRI biomarkers from research tools to clinical mainstays. Harmonizing acquisition protocols and post-processing pipelines ensures reproducibility and comparability across centers and studies, a prerequisite for reliable biomarker validation. This standardization not only accelerates the translation of neuroimaging findings into routine clinical care but also enhances the power of neuroprotection trials. By providing early surrogate endpoints that closely predict long-term outcomes, MRI biomarkers enable trials with smaller sample sizes and faster timelines, hastening the advent of novel therapeutics.

The interplay between MRI and ^1H-MRS represents a paradigm shift in neonatal encephalopathy care. Where once prognosis relied heavily on clinical scoring and physiological parameters, the integration of imaging biomarkers provides objective, quantifiable metrics of brain injury severity. This convergence informs critical decision-making, from therapeutic hypothermia eligibility to anticipatory guidance for families regarding developmental expectations. Furthermore, the evolving consensus underscores the pressing need to incorporate imaging into standard neurocritical care pathways, ensuring timely and targeted interventions.

Therapeutic hypothermia, while revolutionary in reducing mortality and improving outcomes, remains insufficient for a substantial subset of infants with NE. Many survivors still bear significant neurodevelopmental disabilities, highlighting the urgent imperative to refine prognostic tools and to develop adjunctive neuroprotective strategies. Advanced neuroimaging modalities offer hope not only for enhanced prediction but also for monitoring therapeutic efficacy, enabling real-time adjustments and personalized treatment paradigms.

As research progresses, the role of MRI biomarkers in clinical trials extends beyond outcome prediction to serve as surrogate endpoints. Their sensitivity to subtle brain changes offers critical advantages in evaluating new therapeutic agents or protocols. This capacity to detect early neuroprotective effects or identify emerging injury trends can dramatically reduce the duration and cost of trials, fostering rapid innovation in NE management. Moreover, such biomarkers lay the groundwork for precision medicine approaches, stratifying patients based on injury profiles and likely trajectories.

In addition to technical advances, interdisciplinary collaboration remains pivotal in translating MRI and spectroscopy insights into improved patient care. Radiologists, neonatologists, neurologists, and researchers must synergize efforts to refine imaging protocols, interpret complex data, and validate findings against neurodevelopmental outcomes. Training programs in neonatal neuroimaging interpretation and the deployment of centralized image repositories could further enhance expertise dissemination and benchmarking.

The promise of advanced neuroimaging extends beyond immediate neonatal care to influence long-term surveillance and intervention strategies. By charting the evolution of brain injury and recovery, serial MRI assessments can guide rehabilitation efforts, identify windows of neuroplasticity, and inform educational planning. This lifelong perspective emphasizes the foundational role of precise early imaging in optimizing developmental trajectories and quality of life for affected children.

Future opportunities abound as MRI technology continues to evolve. Ultrahigh-field MRI scanners, quantitative susceptibility mapping, and machine learning-assisted image analysis represent frontiers that could deepen insight into neonatal brain injury pathophysiology. Machine learning algorithms, in particular, hold potential for automating image interpretation, standardizing scoring, and integrating multimodal data into predictive models with unprecedented accuracy.

In conclusion, magnetic resonance imaging and spectroscopy have redefined the landscape of neonatal encephalopathy diagnosis and prognosis. Their integration provides a powerful, multifaceted understanding of brain injury patterns, biochemical changes, and functional disruptions. As consensus aligns on standardized protocols and clinical applicability, these imaging modalities are set to become indispensable tools in neonatology. Their influence extends from bedside decision-making to accelerating neuroprotection clinical trials and fostering precision pediatric neurology – a promising horizon for the care of the most vulnerable patients.

Subject of Research: Neonatal encephalopathy; neuroimaging biomarkers; prognostication and outcomes; magnetic resonance imaging and spectroscopy in neonatal brain injury.

Article Title: Magnetic resonance imaging and spectroscopy in neonatal encephalopathy: current consensus position and future opportunities.

Article References:
Laptook, A., Garvey, A.A., Adams, C. et al. Magnetic resonance imaging and spectroscopy in neonatal encephalopathy: current consensus position and future opportunities. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04448-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04448-5

Congenital cytomegalovirus stands out as the most common congenital infection worldwide and a leading non-genetic cause of neurological disabilities in infants. Early diagnosis and accurate neuroimaging evaluation are critical to understanding the extent of central nervous system (CNS) involvement and anticipating neurodevelopmental prognosis. Despite numerous studies highlighting characteristic imaging features, the heterogeneity in terminology and interpretation has hindered cohesive clinical decision-making, often leaving clinicians navigating a fog of ambiguity.

At the heart of this challenge lies the interpretation of neuroimaging modalities such as cranial ultrasound (cUS), magnetic resonance imaging (MRI), and computed tomography (CT) scans. Each brings a unique vantage point to reveal the diverse neuropathological manifestations of cCMV, ranging from intracranial calcifications to cortical malformations and white matter abnormalities. However, the lack of standardized descriptors and consensus guidelines means that what one center may define as “white matter abnormalities” might differ subtly in definition or severity from another, complicating comparisons across studies and institutions.

The authors emphasize the critical role of MRI, particularly advanced sequences, in delineating the extent and nature of brain injury in affected neonates. High-resolution MRI not only visualizes the classic periventricular calcifications but also uncovers subtle findings such as ventriculomegaly, polymicrogyria, and delayed myelination patterns, each of which correlates variably with clinical outcomes. Standardized reporting frameworks, analogous to those used in adult stroke or multiple sclerosis imaging, are posited as essential tools to bring clarity and consistency to neonatal neuroimaging in cCMV.

Further complicating the diagnostic landscape is the timing of imaging studies. The neonatal brain is at a dynamic stage of development, and the progression of injury from the prenatal period through the first months of life influences the radiologic appearance. Early imaging may show limited abnormalities, whereas delayed scans might reveal evolving changes such as cystic encephalomalacia or volume loss. Thus, not only the choice of modality but the timing and repeat imaging protocols must be harmonized to maximize diagnostic yield.

De Vries and colleagues advocate for a multidisciplinary approach, intertwining the expertise of radiologists, neonatologists, infectious disease specialists, and neurologists. The ability to decode imaging findings within the broader clinical and virological context enhances diagnostic accuracy and informs tailored interventions. Moreover, standardized neuroimaging lexicons could facilitate the development of robust, multicenter databases, driving research into prognostic markers and novel therapeutic strategies.

From a technical perspective, the article delves into the intricacies of imaging sequences optimal for detecting cCMV-related pathology. T2-weighted imaging, fluid-attenuated inversion recovery (FLAIR), and susceptibility-weighted imaging (SWI) are underscored for their utility in identifying edema, gliosis, and hemorrhagic components, respectively. Diffusion tensor imaging (DTI), an advanced MRI technique, is spotlighted for its promise in quantifying microstructural white matter integrity, which may correlate with neurodevelopmental outcomes beyond what conventional imaging reveals.

Another dimension tackled by the authors is the need to reconcile disparate terminologies such as “periventricular leukomalacia,” “white matter injury,” and “hypoxic-ischemic patterns” when applied to cCMV. Misclassification or imprecise usage not only muddles clinical communication but also impedes research reproducibility. The proposal for establishing a consensus nomenclature rooted in pathophysiological mechanisms aims to unify the lexicon, fostering clearer understanding and research collaboration.

Furthermore, the article touches upon the role of prenatal imaging in antenatal diagnosis of cCMV. While ultrasound remains the frontline modality, MRI offers superior sensitivity in detecting cortical malformations and migrational anomalies during gestation. However, the challenge lies in standardizing prenatal imaging protocols and signs suggestive of cCMV, which would empower obstetricians and pediatricians to optimize postnatal care pathways and parental counseling.

In the context of therapeutic implications, timely and precise neuroimaging characterization can influence eligibility for antiviral treatment and monitoring strategies. Given emerging data on valganciclovir therapy’s efficacy in mitigating hearing loss and neurodevelopmental deficits, identifying neonates with significant CNS involvement becomes a clinical imperative. Thus, a reproducible imaging framework directly impacts clinical decision-making paradigms.

De Vries et al. also emphasize the influence of evolving neuroimaging technologies in enriching the understanding of cCMV neuropathology. Beyond conventional MRI metrics, functional MRI (fMRI) and magnetic resonance spectroscopy (MRS) may offer insights into cerebral metabolism and functional connectivity alterations, serving as potential biomarkers for neurodevelopmental prognosis. These modalities, however, call for standardization akin to routine structural imaging to avoid variable interpretations across centers.

Multiplicity of findings inherent to cCMV, such as cortical dysplasia coexisting with calcifications and white matter injury, underlines a complex pathogenesis involving viral cytotoxicity, inflammatory cascades, and disrupted neurodevelopmental processes. Understanding this multifaceted injury requires integrated imaging approaches informed by consistent terminology that faithfully represent pathological substrates.

The call to action by the authors extends toward establishing international working groups tasked with developing consensus guidelines and imaging atlases. Such initiatives would, ideally, encompass training modules to promote uniform interpretation across radiologists irrespective of experience, thereby elevating diagnostic reliability globally. The ultimate beneficiary of these strides would be the affected infants and their families, who depend on accurate prognosis and interventions to optimize long-term outcomes.

The broader implications of standardizing neuroimaging language transcend cCMV, serving as a model for handling other congenital infections and developmental disorders where imaging subtleties carry substantial weight in clinical trajectories. This unified approach facilitates meta-analyses, comparative research, and the rapid dissemination of findings integral to evidence-based medicine.

In summation, the 2025 publication by de Vries, Steggerda, and Alarcon shines a spotlight on a pivotal yet under-addressed aspect of cCMV research and clinical management. By underscoring the necessity of a common neuroimaging language, it lays the foundation for improved diagnostic clarity, enhanced interdisciplinary collaboration, and ultimately, better patient care in this vulnerable population. As imaging technology continues to evolve, embracing standardization remains an essential step toward unraveling the intricate neuropathological puzzle presented by congenital cytomegalovirus infection.

Subject of Research: Neuroimaging in congenital cytomegalovirus (cCMV) infection and the need for standardized terminology and interpretation.

Article Title: Neuro-imaging in cCMV infection: let’s try and speak the same language.

Article References:
de Vries, L.S., Steggerda, S.J. & Alarcon, A. Neuro-imaging in cCMV infection: let’s try and speak the same language. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04407-0

Image Credits: AI Generated